Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 23, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 2,600,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,117.72 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.94% of total voting rights).
- Shares in Issue: 5,302,018,549 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,600,000 shares purchased on June 23, 2008. This transaction increased the proportion of Treasury shares held by the company to 8.94% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback.
Investor Verification Checklist
- Verify the total number of shares in issue (5,302,018,549) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (8.94%).
- Note that the purchased shares were cancelled, permanently reducing the company's issued share capital.